Kindred Biosciences Inc represents a strong commitment to improving the lives of animals through innovative veterinary biologics and therapeutics. The company values include integrity, innovation, collaboration, and a dedication to scientific excellence. Kindred Biosciences is driven by a corporate philosophy that emphasizes the importance of research and development, aiming to address unmet veterinary needs and provide effective treatments for various animal species. By leveraging cutting-edge technologies and partnerships, Kindred Biosciences strives to make a positive impact on animal health, while also creating value for its shareholders.

Kindred Biosciences Inc primarily operates in the United States.

Since its establishment, Kindred Biosciences Inc has accomplished several significant milestones. The company successfully received approval from the Food and Drug Administration (FDA) for their groundbreaking therapies, such as Zimeta, Mirataz, and KIND-016. Additionally, Kindred Biosciences Inc has entered into strategic partnerships and collaborations with renowned pharmaceutical companies, enabling them to expand their research and development capabilities. These partnerships have played a pivotal role in advancing the company's pipeline, leading to the development of innovative treatments for various animal diseases. Kindred Biosciences Inc continues to exhibit strong commitment towards improving animal health and welfare through their pioneering achievements and ongoing efforts.

Kindred Biosciences Inc, a biopharmaceutical company, has a fascinating history and background. It was founded in 2012 and is headquartered in California, United States. The company specializes in developing innovative medicines for veterinary use. Kindred Biosciences is committed to enhancing the lives of pets by focusing on unmet medical needs. With a highly experienced team and state-of-the-art facilities, they strive to develop effective therapies and treatments for various animal diseases. Kindred Biosciences has gained recognition for its dedication to animal health and its successful development of novel biologics. Continuously expanding its product portfolio, the company seeks to revolutionize veterinary medicine.

The main competitors of Kindred Biosciences Inc in the market are Zoetis Inc., Elanco Animal Health Inc., and IDEXX Laboratories Inc.

Kindred Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Kindred Biosciences Inc, a biopharmaceutical company, focuses on veterinary medicine. They develop innovative therapeutics for animals, aiming to improve the lives of pets and horses. Kindred Biosciences creates drugs for various conditions that affect animals, including allergies, infections, and gastrointestinal disorders. Their mission is to provide effective and safe medications to improve the well-being of companion animals. With a strong commitment to research and development, Kindred Biosciences pioneers advancements in animal healthcare, seeking to address unmet medical needs in the veterinary industry and contribute to the overall betterment of animal health.

مُعامل القيمة السوقية إلى الأرباح لـ Kindred Biosciences هو 0.

مُعامِل القيمة إلى المبيعات Kindred Biosciences هو ١٦٫٦٧.

نقاط جودة AlleAktien لـ Kindred Biosciences هي 1/10.

المتوقعة Kindred Biosciences الإيرادات هي ٢١٫٨٠ مليون. USD.

لا يمكن حساب الربح لـ Kindred Biosciences في الوقت الحالي.

Kindred Biosciences Inc. is a biopharmaceutical company focused on the development of innovative animal health products. The company aims to improve animal lives and provide pet owners with innovative and effective therapies. It is divided into three main business areas: Biologics, small molecules, and diagnostics. In the field of Biologics, Kindred Biosciences develops innovative biopharmaceutical products for animals. The focus is on researching and developing antibodies and proteins that block or neutralize disease-causing target molecules. Examples include Zimeta, an injectable medication for treating fever in horses, and KIND-010, an antibody for treating atopic dermatitis in dogs. The small molecules division focuses on developing chemical compounds for treating diseases in animals. Kindred Biosciences uses its own technology platform to identify and optimize molecules that bind to specific target molecules in the body. An example is Mirataz, a topical gel for treating cats with compulsive disorders. The diagnostics division offers a wide range of tests and instruments for the rapid and reliable diagnosis of animal diseases. For example, the SUCCEED Equine Fecal Blood Test measures the worm burden in horses, allowing for targeted deworming. Kindred Biosciences also conducts extensive research and development to continuously expand and improve its portfolio of animal health products. The company collaborates closely with the veterinary community and utilizes advanced technologies and methods such as protein engineering and CRISPR/Cas9 to explore new therapeutic approaches. Overall, Kindred Biosciences offers a broad range of animal health products valued by both veterinarians and pet owners. The company stands out for its strong research and development efforts, close collaboration with the veterinary community, and innovative technologies. With a strong market position and solid growth strategy, Kindred Biosciences is an important player in the animal health products market.

يوزع Kindred Biosciences أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Kindred Biosciences في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـKindred Biosciences هو US4945771099.

رمز WKN لـ Kindred Biosciences هو A1XA6K.

الرمز المُختصر لـ Kindred Biosciences هو KIN.

خلال آخر 12 شهراً، دفعت Kindred Biosciences توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Kindred Biosciences خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Kindred Biosciences هي .

Kindred Biosciences يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Kindred Biosciences دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Kindred Biosciences يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Kindred Biosciences المُعلن عنها في ١٨‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١٨‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١٨‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Kindred Biosciences 0 USD كأرباح أسهم.

يتم توزيع أرباح Kindred Biosciences بالعملة USD.